Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer - A phase II trial

Prostate Cancer and Prostatic Diseases

Volumn 7, Issue 1, 2004, Pages 45-49

  Bernardi, D ^a   Talamini, R ^a   Zanetti, M ^a   Simonelli, C ^a   Vaccher, E ^a   Spina, M ^a   Tirelli, U ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Chemotherapy; Hormone resistance; Mitoxantrone; Prostate cancer; Vinorelbine

Indexed keywords

CISPLATIN; DOXORUBICIN; ESTRAMUSTINE; MITOXANTRONE; NAVELBINE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE; TAXANE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; GASTROINTESTINAL TOXICITY; HORMONE RESISTANCE; HUMAN; INFECTION; LEUKOPENIA; MALE; METASTASIS; NEUROTOXICITY; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SEROLOGY; THROMBOCYTOPENIA; THROMBOSIS;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MITOXANTRONE; PREDNISONE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; VINBLASTINE;

EID: 1842424889     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500685     Document Type: Article

References (28)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1997; 47: 5-27.
2. Goktas S, Crawford ED. Optimal hormonal therapy for advanced prostatic carcinoma. Semin Oncol 1999; 26: 162-173.
3. Oh WK. Chemotherapy for patients with advanced prostate carcinoma. Cancer 2000; 88: 3015-3021.
4. Culine S, Droz J-P. Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: A decade of progress? Ann Oncol 2000; 11: 1523-1530.
5. Eisenberger MA. Chemotherapy for prostate carcinoma. NCI Monogr 1988; 7: 151-163.
6. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993; 71: 1098-1099.
7. Dawson NA. Response criteria in prostatic carcinoma. Semin Oncol 1999; 26: 174-184.
8. Bubley GJ et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen working group. J Clin Oncol 1999; 17: 3461-3467.
9. Tannock IF et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756-1764.
10. Kantoff PW et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999; 17: 2506-2513.
11. Isaacs JT. The biology of hormone-refractory prostate cancer: why does it develop? Urol Clin North Am 1999; 26: 263-273.
12. Depierre A et al. A phase II study of navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol 1991; 14: 115-119.
13. Le Chevalier T et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancers: Results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360-367.
14. Marty M et al. A review of antitumour activity of vinorelbine in breast cancer. Drugs 1992; 44: 29-35.
15. Fields-Jones S et al. Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: A phase II trial. Ann Oncol 1999; 10: 1307-1310.
16. Morant R et al. Vinorelbine in androgen-independent metastatic prostate carcinoma - a phase II study. Eur J Cancer 2002; 38: 1626-1632.
17. WHO Handbook for reporting results of cancer treatment. WHO Offset Publication No. 48. Geneva, Switzerland, World Health Organization, 1979.
18. Oudard S et al. Phase II study of vinorelbine in patients with androgen-independent prostate cancer. Ann Oncol 2001; 12: 847-852.
19. Houde RW. Methods for measuring clinical pain in humans. Acta Anaesthesiol Scand 1982; 74:(Suppl): 25-29.
20. Kelly WK et al. Prostate specific antigen as a measure of disease outcome in metastatic hormono-refractory prostate cancer. J Clin Oncol 1993; 11: 607-615.
21. Sweeney CJ et al. A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. Ann Oncol 2002; 13: 435-440.
22. Colleoni M et al. Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer. Am J Clin Oncol 1997; 20: 383-386.
23. Smith MR et al. Vinorelbine and estramustine in androgen-independent metastatic prostate cancer. A phase II study. Cancer 2000; 89: 1824-1828.
24. Hudes GR et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997; 15: 3156-3163.
25. Smith DC et al. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 1999; 17: 1664-1671.
26. Savarese DM et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780. J Clin Oncol 2001; 19: 2509-2516.
27. Oudard S et al. Preliminary results of a phase II randomized trial of docetaxel, estramustine and prednisone - two schedules versus mitoxantrone and prednisone in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 2002; 21: 177a (abstract 706).
28. Sinibaldi VJ et al. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 2002; 94: 1457-1465.